U.S. Markets closed

The blood screening market is projected to reach USD 3.3 billion by 2024 from USD 2.2 billion in 2019, at a CAGR of 8.7%

NEW YORK, Dec. 30, 2019 /PRNewswire/ --

Increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens are driving the overall growth of the blood screening market

Read the full report: https://www.reportlinker.com/p04603857/?utm_source=PRN

The blood screening market is projected to reach USD 3.3 billion by 2024 from USD 2.2 billion in 2019, at a CAGR of 8.7%. Growth in this market is driven by the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens. Technological advancements and developing economies are expected to present opportunities for growth for players in the blood screening market. However, the need to reduce blood screening prices is a major factor in challenging market growth.

Nucleic Acid Testing (NAT) segment accounted for the larger share of the blood screening market, by technology, in 2018
The blood screening market, by technology, has been segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assays (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS).The NAT segment dominates the blood screening market, by technology, primarily due to the increasing number of blood donations and the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies.

Based on type, the blood screening market for NAT is segmented into transcription-mediated amplification (TMA) and real-time PCR. Among these, the TMA segment accounts for the larger market share due to the higher sensitivity of this assay.

Blood banks to register the highest growth in the blood screening market during the forecast period
Based on end users, the blood screening market is segmented into blood banks and hospitals.The blood bank segment accounted for the larger market share in 2018 and is projected to witness a higher growth rate during the forecast period.

This can be attributed to the increasing demand for donated blood, a growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, increasing the number of donations worldwide, and growth in government funding to charitable trusts.

North America will continue to dominate the blood screening market during the forecast period
Based on region, the blood screening market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.In 2018, North America accounted for the largest market share, followed by Europe.

Factors such as the increasing demand for donated blood, the rising number of blood donations, the growing prevalence of infectious diseases, and the increasing prevalence of newer pathogens, the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the region are driving the growth of the blood screening market in North America.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 - 36%, Tier 2 - 45%, and Tier 3 - 19%
• By Designation: C-level - 33%, D-level - 40%, and Others - 27%
• By Region: North America - 39%, Europe - 28%, Asia Pacific - 19%, Latin America- 9% and the Middle East and Africa- 5%

Companies Profiled in the Report
Prominent players in the blood screening market include Grifols (Spain), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), BioMérieux (France), Bio-Rad Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US) ,Ortho Clinical Diagnostics, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy), GFE (Germany), Trinity Biotech (Ireland), Merck Millipore (Germany), GE Healthcare (US), Perkin Elmer (US), Bio-Techne Corporation (US), and J Mitra & Co. Pvt. Ltd (India).

Research Coverage:
This report provides a detailed picture of the global blood screening market.It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, end user, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall blood screening market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies.

This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, opportunities, and trends.

Read the full report: https://www.reportlinker.com/p04603857/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision

View original content:http://www.prnewswire.com/news-releases/the-blood-screening-market-is-projected-to-reach-usd-3-3-billion-by-2024-from-usd-2-2-billion-in-2019--at-a-cagr-of-8-7-300979752.html

SOURCE Reportlinker